This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI >=27.
Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken.
The primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples).
Secondary objectives will be
* To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication.
* To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide/Weight loss.
* To see how the changes seen in the tissue relate to weight loss.

Start Date09 Mar 2026

Sponsor / Collaborator

NHS Greater Glasgow and Clyde

[+2]

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Jan 2026

Sponsor / Collaborator

The University of California, San Francisco

CTRI/2025/11/097895

/ Not yet recruitingNot ApplicableIIT

To evaluate efficacy and safety of Ixekizumab in Indian Psoriasis Patients. - nil

Start Date18 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Ixekizumab

100 Translational Medicine associated with Ixekizumab

100 Patents (Medical) associated with Ixekizumab

1,182

Literatures (Medical) associated with Ixekizumab

01 Apr 2026·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

KLRB1 and IL12RB1 are pretherapeutic predictors of time to relapse in patients with psoriasis treated with IL-17 blockade

Article

Author: Xue, Feng ; Xu, Xintian ; Wang, Hailun ; Zhang, Li ; Zheng, Jie ; Pan, Meng ; Li, Xia ; Cao, Han ; Hao, Pei ; Quan, Cheng ; Chen, Lihong ; Le, Yunchen

BACKGROUND:

Relapse of psoriasis after the cessation of treatment remains an unresolved clinical challenge.

OBJECTIVE:

To identify predictors of risk of relapse in patients with psoriasis treated by interleukin (IL) 17 blockade (ixekizumab) and to investigate longitudinal dynamics driving relapse.

METHODS:

Longitudinal skin transcriptomes were collected from 23 patients across baseline, psoriasis area and severity index 75 at week 8, and relapse phases. An iterative random forest regression model and SHapley Additive exPlanation values were used to determine key predictive genes of relapse. Profiling of immune-infiltrating cells and time-series-based clustering were performed to identify longitudinal transcriptomic signatures.

RESULTS:

KLRB1 and IL12RB1 were identified as key predictive genes by a machine learning model and validated by immunofluorescence on baseline skin biopsies. Multivariable Cox regression built by KLRB1 and IL12RB1 stratified patients with high risk of relapse (log-rank test P = .0013). Reactivation of CD4⁺ memory T cells, dendritic cells, and mast cells was associated with relapse; KLRB1 and IL12RB1 were positively correlated with the activated state of these immune-infiltrating cells.

LIMITATIONS:

Patients were recruited from a single center, and all were treated with ixekizumab.

CONCLUSION:

Patients with psoriasis who exhibit elevated levels of KLRB1 and IL12RB1 at baseline have a higher risk of relapse after ixekizumab withdrawal.

01 Apr 2026·Rheumatology and Therapy

Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging

Article

Author: Li, Jingyang ; Liu, Dongzhou ; Sun, Lingyun ; Dai, Lie ; Zhu, Xiaoxia ; Zou, Hejian ; Wang, Yongfu ; Tan, Chunyu ; Li, Zhijun ; Yan, Yan ; Dong, Lingli ; Wu, Huaxiang ; Hu, Jiankang ; Xiao, Zhengyu ; Li, Hongying

INTRODUCTION:

We report an exploratory subgroup analysis of a Chinese phase 3 study to investigate the effect of baseline inflammation measured by magnetic resonance imaging (MRI) on ixekizumab efficacy in radiographic axial spondyloarthritis (r-axSpA).

METHODS:

Adults with r-axSpA were randomized (1:1) to receive ixekizumab 80 mg every 4 weeks (IXEQ4W) or placebo for 16 weeks. Endpoints analyzed by baseline Spondyloarthritis Research Consortium of Canada (SPARCC) MRI spine or sacroiliac joint (SIJ) inflammation score (< 2 or ≥ 2; elevated inflammation defined as score ≥ 2) were: Assessment of SpondyloArthritis International Society 40 (ASAS40); Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50); Ankylosing Spondylitis Disease Activity Score (ASDAS) < 2.1; ASDAS clinically important improvement (CII; change from baseline ≥ 1.1); Patient Global Assessment of Disease Activity (PtGA); spinal pain; nocturnal spinal pain; stiffness/inflammation; function; fatigue; Short Form-36 Physical Component Score (SF-36 PCS); European Quality of Life 5 Dimensions 5 Levels visual analog scale (EQ-5D-5L VAS).

RESULTS:

Overall, 145 patients were included. At Week 16, ASAS40 response rates were numerically improved with IXEQ4W versus placebo in the SPARCC MRI spine score < 2 subgroup (40.9% vs. 14.3%; p = 0.088) and significantly improved in the ≥ 2 subgroup (37.3% vs. 5.9%; p < 0.001). ASAS40 response rates were significantly improved in the SPARCC MRI SIJ score < 2 (34.4% vs. 8.6%; p < 0.05) and ≥ 2 (41.5% vs. 8.1%; p < 0.001) subgroups. Similar results were obtained on BASDAI50, ASDAS < 2.1, and ASDAS CII. IXEQ4W significantly improved PtGA, inflammation, and fatigue across all subgroups. Spinal and nocturnal spinal pain were significantly improved in the SPARCC MRI spine score ≥ 2 subgroup and both SPARCC MRI SIJ score subgroups. Function and SF-36 PCS were significantly improved in the SPARCC MRI spine score ≥ 2 subgroup. There were no significant differences in EQ-5D-5L VAS.

CONCLUSION:

These findings support IXEQ4W as an effective treatment for Chinese patients with r-axSpA, irrespective of baseline MRI inflammation.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT04285229.

01 Apr 2026·Dermatology and Therapy

Comparison of the Effects and Safety of Planned Limited-Time Withdrawal Versus Continuous Maintenance of Interleukin Inhibitors in Patients with Psoriasis: A Systematic Review and Network Meta-Analysis

Review

Author: Gomes, Ciro M ; de C Mesquita, Kleyton ; Zanghelini, Fernando ; Canabrava, Paola B E ; Barroso, Letícia F ; de Sena, Rodrigo R

INTRODUCTION:

Recent trials with withdrawal arms in patients with psoriasis have highlighted the need for updated clinical guidance. The aim of this investigation was to compare the effects and safety of planned limited-time withdrawal versus continuous maintenance of interleukin (IL) inhibitors in patients with psoriasis.

METHODS:

On August 5, 2025, the following platforms were systematically searched: PubMed, Embase, Clarivate (Web of Science), Scopus, and Ovid. Titles and abstracts, followed by full-text articles, were independently screened by two reviewers, with any disagreements being resolved by a third reviewer. Certainty of evidence was evaluated via the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Network meta-analyses for the Psoriasis Area and Severity Index (PASI) 90 and PASI100 outcomes were performed. The risk ratio (RR) of relapse was ranked using the surface under the cumulative ranking curve (SUCRA) metric.

RESULTS:

A total of 7444 records were retrieved, 54 of which included data from 18 different trials. The data revealed a total of 2995 patients who were subjected to anti-IL withdrawal regimens that were eligible for comparison with anti-IL maintenance. For the PASI90 outcome, the network meta-regression, adjusted for a post-withdrawal follow-up duration of 40-48 weeks, indicated that bimekizumab demonstrated a RR for relapse (RR 5.36; 95% confidence interval (CI) 3.45-8.34; SUCRA 0.685) comparable to that of guselkumab (RR 7.45; 95% CI 4.97-11.19; SUCRA 0.412) and lower than that of ixekizumab (RR 17.45; 95% CI 10.22-29.80; SUCRA 0.006). No significant difference in adverse event rates was observed between the anti-IL withdrawal and maintenance groups.

CONCLUSIONS:

Compared with continued treatment, planned withdrawal of anti-IL therapy is associated with a largely superior risk of relapse, without any reduction in the incidence of adverse events. Moreover, bimekizumab withdrawal demonstrated better outcomes than ixekizumab withdrawal did according to the PASI90 outcome.

STUDY REGISTRATION:

This study was prospectively registered on PROSPERO (identification number CRD420251118724).

135

News (Medical) associated with Ixekizumab

30 Apr 2026

·www.prnewswire.com

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound. Q1 2026 EPS increased by 170% to $8.26 on a reported basis and increased by 156% to $8.55 on a non-GAAP basis. The Q1 2026 reported and non-GAAP EPS included $0.52 of acquired IPR&D charges compared to $1.72 in Q1 2025. Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00. Regulatory progress included U.S. FDA approval of Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. Pipeline progress included positive Phase 3 results from Foundayo (orforglipron) in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk, Jaypirca in combination with venetoclax and rituximab in relapsed or refractory CLL or SLL, Taltz and Zepbound used together for adults with psoriasis and obesity or overweight, and retatrutide in type 2 diabetes. Business development activity included the agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics. Company announces planned Investment Community Meeting for December 7, 2026 INDIANAPOLIS, April 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2026 and provided updated 2026 financial guidance. "2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion," said David A. Ricks, Lilly chair and CEO. "A key milestone was the U.S. FDA approval of Foundayo—the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s. We also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly's future growth through four acquisitions." Financial Results A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)." First-Quarter Reported Results In Q1 2026, worldwide revenue was $19.8 billion, an increase of 56% compared with Q1 2025, driven by a 65% increase in volume, partially offset by a 13% decrease due to lower realized prices. Key Products1 revenue grew to $13.4 billion in Q1 2026, led by Mounjaro and Zepbound. Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 160% in Q1 2026 compared to Q1 2025. Revenue in the U.S. increased 43% to $12.1 billion, driven by a 49% increase in volume, partially offset by a 7% decrease due to lower realized prices. The increase in U.S. volume was driven by Zepbound and Mounjaro and the decline in realized prices was primarily driven by Zepbound and Taltz. Revenue outside the U.S. increased 81% to $7.7 billion, driven by a 95% increase in volume, partially offset by a 25% decrease due to lower realized prices. The lower realized prices outside the U.S. were driven primarily by the addition of Mounjaro to the National Reimbursed Drug List (NRDL) in China. The volume increase outside the U.S. was driven by Mounjaro. Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. Gross margin increased 54% to $16.2 billion in Q1 2026. Gross margin as a percent of revenue was 81.9%, a decrease of 0.6 percentage points versus the same quarter last year. The change was primarily driven by lower realized prices. In Q1 2026, research and development expenses increased 28% to $3.5 billion, or 18% of revenue, driven by continued investments in the company's early and late-stage portfolio. Marketing, selling, and administrative expenses increased 19% to $2.9 billion in Q1 2026, primarily driven by promotional efforts supporting ongoing and planned launches. In Q1 2026, the company recognized acquired in-process research and development (IPR&D) charges of $584 million compared with $1.6 billion in Q1 2025. The Q1 2025 charges primarily related to the acquisition of Scorpion Therapeutics, Inc.'s PI3Kα inhibitor program STX-478. Asset impairment, restructuring and other special charges of $279 million in Q1 2026 were primarily related to litigation matters. In Q1 2025, there was a charge of $35 million related to intangible asset impairments. The effective tax rate was 16.4% in Q1 2026 compared with 20.2% in Q1 2025, primarily driven by the unfavorable tax impact of a non-deductible acquired IPR&D charge in Q1 2025. The 2026 and 2025 effective tax rates were impacted by net discrete tax benefits in each period. In Q1 2026, net income and earnings per share (EPS) were $7.4 billion and $8.26, respectively, compared with net income of $2.8 billion and EPS of $3.06 in Q1 2025. EPS in Q1 2026 and Q1 2025 included acquired IPR&D charges of $0.52 and $1.72, respectively. First-Quarter Non-GAAP Measures On a non-GAAP basis, Q1 2026 gross margin increased 54% to $16.4 billion. Gross margin as a percent of revenue was 82.6%, a decrease of 0.9 percentage points versus the same quarter last year. The change was primarily driven by lower realized prices. The non-GAAP effective tax rate was 16.5% in Q1 2026 compared with 20.2% in Q1 2025, primarily driven by the unfavorable tax impact of a non-deductible acquired IPR&D charge in Q1 2025. The 2026 and 2025 effective tax rates were impacted by net discrete tax benefits in each period. On a non-GAAP basis, Q1 2026 net income and EPS were $7.7 billion and $8.55, respectively, compared with net income of $3.0 billion and EPS of $3.34 in Q1 2025. Non-GAAP EPS in Q1 2026 and Q1 2025 included acquired IPR&D charges of $0.52 and $1.72, respectively. For further detail on non-GAAP measures, see the reconciliation below as well as the "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)" table later in this press release. Selected Revenue Highlights Mounjaro For Q1 2026, worldwide Mounjaro revenue increased 125% to $8.7 billion. U.S. revenue was $4.2 billion, an increase of 59%, reflecting strong demand, partially offset by lower realized prices. Lower realized prices were partially offset by a favorable one-time adjustment to estimates for rebates and discounts in Q1 2026. Revenue outside the U.S. increased to $4.4 billion compared with $1.2 billion in Q1 2025, primarily driven by volume growth, partially offset by lower realized prices driven by the addition of Mounjaro to the NRDL within the China market. Zepbound For Q1 2026, U.S. Zepbound revenue increased 79% to $4.1 billion, compared with $2.3 billion in Q1 2025, primarily driven by strong demand, partially offset by lower realized prices, including previously announced reductions in cash pay prices. Lower realized prices were partially offset by a favorable one-time adjustment to estimates for rebates and discounts in Q1 2026. Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including: For information on important public announcements, visit the news section of Lilly's website. 2026 Financial Guidance In addition to providing guidance for GAAP revenue, Lilly provides guidance for certain non-GAAP measures. The following table summarizes the company's updated full-year 2026 non-GAAP financial guidance, reflecting the strong revenue performance in Q1: Webcast of Conference Call As previously announced, investors and the general public can access a live webcast of the Q1 2026 financial results conference call through a link on Lilly's website at investor.lilly.com/webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website. Non-GAAP Financial Measures Certain financial information is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Historical non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2026 financial guidance (other than revenue) is provided on a non-GAAP basis, as described in "2026 Financial Guidance" above. Non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news. F-LLY Cautionary Statement Regarding Forward-Looking Statements This press release and the related attachments contain management's intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "estimate", "project", "intend", "expect", "believe", "target", "plan", "anticipate", "may", "could", "aim", "seek", "will", "continue", and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals and the ability of the company's clinical trials to meet expectations; the impact and uncertain outcome of acquisitions and business development transactions and related costs; intense competition affecting the company's products, pipeline, or industry; market uptake of launched products and indications; continued pricing pressures and the impact of actions of governmental and private actors affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; the implementation of our voluntary agreement with the U.S. government related to drug pricing and access; Developments or uncertainties related to our or competitive products, including as may relate to safety or efficacy concerns; dependence on relatively few products or product classes for a significant percentage of the company's total revenue and a consolidated supply chain; the expiration of intellectual property protection for certain of the company's products and competition from generic and biosimilar products; the company's ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data and violations of data protection laws or regulations; issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to the company's and third-party facilities; reliance on third-party relationships and outsourcing arrangements; the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; fluctuations in foreign currency exchange rates, changes in interest rates and inflation or deflation; significant and sudden declines or volatility in the trading price of the company's common stock and market capitalization; litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property; changes in tax law and regulations, tax rates, or events that differ from our assumptions related to tax positions; regulatory changes, developments, and uncertainty; regulatory oversight and actions regarding the company's operations and products; regulatory compliance problems or government investigations; risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products; actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; asset impairments and restructuring charges; and changes in accounting and reporting standards. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements contained in this press release and the related attachments, which, except as otherwise noted, speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements contained in this press release and the related attachments to reflect events or circumstances after the date of this release. Website Information The information contained on, or that may be accessed through, our website or any third-party website is not incorporated by reference into, and is not a part of, this earnings release. Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. SOURCE Eli Lilly and Company 21% more press release views with Request a Demo

Drug ApprovalClinical ResultFinancial StatementAcquisitionPhase 3

06 Apr 2026

·www.drugs.com

AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy

MONDAY, April 6, 2026 -- Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver. Joseph F. Merola, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues evaluated the efficacy and safety of IXE+TZP versus IXE alone in adults with active PsA and overweight with one or more weight-related comorbidity or obesity. The analysis included 138 individuals on IXE+TZP and 133 on IXE as part of the TOGETHER-PsA phase 3b study. The researchers found that 71.6 percent of participants had psoriasis, and 18.8 percent had failed at least two classes of advanced therapies. Just under one-third of participants (31.7 percent) achieved the primary outcome of simultaneous achievement of American College of Rheumatology 50 percent (ACR50) improvement and ≥10 percent weight reduction at week 36 with IXE+TZP compared with 0.8 percent for IXE alone. There was a meaningful difference in ACR50 in IXE+TZP (33.5 percent) versus IXE alone (20.4 percent), with a significant improvement seen as early as week 4. IXE+TZP led to a significant difference in absolute Psoriasis Area and Severity Index change from baseline. Additionally, there were significant improvements in measures of physical function, fatigue, and mental and physical health. No new safety signals were seen. Treatment discontinuations due to adverse events were similar between treatment groups. "Significant comprehensive improvement in disease activity was demonstrated with IXE+TZP compared to IXE alone in active PsA, with no new safety concerns," the authors write. The study was sponsored by Eli Lilly, the manufacturer of ixekizumab and tirzepatide. More Information

Phase 3Clinical Result

31 Mar 2026

·www.prnewswire.com

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78% experienced significant itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients 80% of patients achieved durable results without the need for topical corticosteroids March 27, 2026 -- New long-term data show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver.1 "These data underscore our unwavering commitment to expanding what people with moderate-to-severe atopic dermatitis can achieve with treatment," said Adrienne Brown, executive vice president and president, Lilly Immunology. "For too long the focus has been around symptom management and many patients struggle to achieve consistent disease control despite cycling through topical treatments. EBGLYSS is helping transform this treatment paradigm—allowing people the opportunity to reimagine life without the frequent interruptions caused by flares or topicals applied 2-3 times per day." EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity and slow dissociation rate.2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.5,6 In the ADlong study, the majority of patients achieved a high bar of near-complete skin clearance and significant itch relief with up to four years of continuous EBGLYSS treatment. Most patients (77%) were on EBGLYSS monotherapy, and 80% achieved results without topical corticosteroids. In addition, 80% achieved these outcomes with EBGLYSS monthly maintenance dosing during the study. The safety of EBGLYSS in the first year of the ADlong study was consistent with the known profile in patients with moderate-to-severe atopic dermatitis, regardless of dose frequency, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation. Reported treatment-related adverse events in the study included conjunctivitis (6.9%) and injection-site reactions (0.6%). The ADlong study is ongoing and will continue for an additional year of treatment. These results reinforce previously reported long-term results for EBGLYSS for patients with moderate-to-severe atopic dermatitis. In addition, a post-hoc analysis presented at Maui Derm Hawaii 2026 on EASI-75 stable responders showed less than one flare per patient per year with EBGLYSS monthly maintenance dosing used as monotherapy.7 "There is still an unmet need for people with moderate-to-severe atopic dermatitis who frequently experience unpredictable flares and are in need of treatment options that go beyond just symptomatic relief and address the underlying inflammation driving skin symptoms and persistent itch," said Emma Guttman-Yassky, M.D., Ph.D., The Waldman Professor and Health System Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York. "These four-year findings reinforce that EBGLYSS has the potential to deliver durable disease control, helping patients flare less with or without topicals." Lilly continues to raise the standard of care in dermatology and boldly invest in the next wave of immunology innovation, which includes big bets on next-generation modalities, the targeted expansion of small molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsA and TOGETHER-PsO trials investigating the concomitant use of ixekizumab and an incretin-based therapy to treat adults with psoriatic disease and obesity or overweight with at least one additional weight-related comorbid condition. Lilly's investigational therapies include DC-853, a novel oral IL-17 inhibitor being studied for psoriasis, and eltrekibart, a novel monoclonal antibody that targets neutrophil-driven inflammation and is being assessed in hidradenitis suppurativa. Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe. ADlong (NCT05916365) open-label extension study is evaluating the long-term safety and efficacy of EBGLYSS 250 mg dosed every four weeks (Q4W) in patients with moderate-to-severe atopic dermatitis for a total of 108 weeks. Adult and adolescent (ages 12–17, weighing ≥40 kg) patients from select countries in Europe who completed the 100-week ADjoin extension study, including patients who completed the ADore trial (52 weeks), the ADhere trial (16 weeks), and Week 16 responders who completed the ADvocate 1 and 2 trials (52 weeks), were eligible to enroll in ADlong. Patients (N=174) in this analysis receive open-label EBGLYSS 250 mg Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose). The approved maintenance dose of EBGLYSS is 250 mg once monthly, after taking EBGLYSS every two weeks for the four-month initial dosing phase (or later once achieving adequate clinical response).8 Intermittent use of topical rescue medications and short-term systemic treatments was allowed.1 If response was below EASI-50, Q2W could be used and thereafter Q4W could be resumed. EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate.3,4,8 EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of eczema, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13.8 The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating over 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin), adolescent open-label (ADore) and pediatric (ADorable 1 and 2) studies. EBGLYSS is also being studied in allergic rhinitis and chronic rhinosinusitis with nasal polyps. EBGLYSS was approved in the U.S., Japan and Canada in 2024 and in the European Union in 2023. EBGLYSS is a first-line biologic treatment with the option of monotherapy that offers once-monthly maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies.8 EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is a single monthly injection (250 mg every four weeks) which can be used with or without topical corticosteroids.8 Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans. We have expanded Medicaid coverage and are pursuing similarly broad Medicare coverage as part of Lilly's health equity and affordability initiative. Through Lilly Support Services, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients. Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. 1 Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial. American Academy of Dermatology Annual Meeting. March 2026 2 Simpson EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017 3 Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7 4 Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.024 5 Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954 6 Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018 7 Merola J, et al. Patients with Atopic Dermatitis with a Stable Response to Lebrikizumab Flare Less in a Long-Term Study: A Post-hoc Analysis of the ADjoin Study. Maui Derm Hawaii. January 2026 8 EBGLYSS. Prescribing Information. Lilly USA, LLC. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

100 Deals associated with Ixekizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10071	Ixekizumab	L04AC13	DB11569

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Spondylarthritis	Canada	Eli Lilly & Co.	11 Aug 2016
Erythrodermic psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis vulgaris	Japan	Eli Lilly Japan KK	04 Jul 2016
Pustular psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Ankylosing Spondylitis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enthesitis-Related Arthritis	NDA/BLA	European Union	Eli Lilly & Company (Ireland) Ltd.	24 Jul 2025
Juvenile Idiopathic Arthritis	NDA/BLA	European Union	Eli Lilly & Company (Ireland) Ltd.	24 Jul 2025
Obesity	Phase 3	United States	Eli Lilly & Co.	24 Sep 2024
Chronic large plaque psoriasis	Phase 3	United States	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Japan	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Australia	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Canada	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Denmark	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Germany	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Hungary	Eli Lilly & Co.	16 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06588296 (TOGETHER-PsA, Pubmed \| Arthritis Rheumatol)	Phase 3	Arthritis, Psoriatic	271	Ixekizumab + Tirzepatide	wabkxesepw(vuybbvrbpe) = yithehukqi mgdbhnqswj (wgitjtynhy ) View more	Positive	28 Mar 2026
				Ixekizumab	wabkxesepw(vuybbvrbpe) = ocgfuiuvdk mgdbhnqswj (wgitjtynhy ) View more
AAD2026	Not Applicable	Psoriasis	1,043	IL-17i	hcipreamdt(rssimpuyuc) = ehfuixctnd rhbvohdcou (tblehwctkj )	Positive	27 Mar 2026
				Etanercept	hcipreamdt(rssimpuyuc) = sbzrsppxhj rhbvohdcou (tblehwctkj )
AAD2026	Not Applicable	Plaque psoriasis	738	Apremilast	uwhfcggdyu(xbgkzfaofv) = ebfqvlfbfk hlaziaakdi (jxllnbmory ) View more	Positive	27 Mar 2026
				Etanercept	zziscpruyz(fvxadqofhb) = oxcufkcaiv pyqzredxdd (muwjkvevdb ) View more
NCT01646177 (UNCOVER-3, AAD2026)	Phase 3	Psoriasis	385	Ixekizumab	fbhtiofikr(ygbweessed) = itpsajxnpy gmcpyfqqqq (uakyhehuqk ) View more	Positive	27 Mar 2026
NCT04527380 (COSPIRIT-JIA, Pubmed \| Lancet Rheumatol)	Phase 3	Enthesitis-Related Arthritis \| Arthritis, Psoriatic	101	Ixekizumab (biological DMARD naive)	awkxollour(ovmupdufsy) = hkocwrwmlp fqktbqvigi (ceyqkernyc, 82.4 - 97.6)	Positive	01 Mar 2026
				Ixekizumab (biological DMARD experienced)	awkxollour(ovmupdufsy) = pplzarassk fqktbqvigi (ceyqkernyc, 70.7 - 100.0)
NCT06588283 (TOGETHER-PsO, Company_Website) Manual	Phase 3	Psoriasis \| Overweight \| Obesity	274	Taltz + Zepbound	zevazrpkkd(fcndriykmx) = bqftfdztkt xvfnlfamjg (gnirlwmvqf ) Met View more	Positive	18 Feb 2026
				Taltz	zevazrpkkd(fcndriykmx) = dlgdtincqh xvfnlfamjg (gnirlwmvqf ) Met View more
NCT06588296 (TOGETHER-PsA, Company_Website) Manual	Phase 3	Arthritis, Psoriatic \| Overweight \| Obesity	271	Taltz (ixekizumab) + Zepbound (tirzepatide)	usidblqztu(zolqlficmy) = aemdvjeiyn wskdigbpfv (uemkazknwn ) Met View more	Superior	08 Jan 2026
				Taltz (ixekizumab)	usidblqztu(zolqlficmy) = szxsacveub wskdigbpfv (uemkazknwn ) Met View more
ACR2025	Not Applicable	Arthritis, Psoriatic	237	risankizumabguselkumabab + risankizumabguselkumab	slyoticnxc(lppolzvrnk) = czrkubbzaa bgebygqxeu (fzcxjojvls )	Positive	24 Oct 2025
ACR2025	Not Applicable	Psoriasis \| Ankylosing Spondylitis	181,052	Secukinumab	zugwrsmrut(biyvszoklb) = mxlueofsln mohvceozbd (vwjayyeyhu ) View more	Positive	24 Oct 2025
NCT05855967 (CTgov)	Phase 4	Plaque psoriasis \| Arthritis, Psoriatic	250	Ixekizumab (Ixekizumab - PsO With no Active PsA)	uhewgjgsoz = grwqncfzup fybjwzmqfy (zalcqoytcj, sbogdcptjn - mebjenlidt) View more	-	22 Aug 2025
				Ixekizumab (Ixekizumab - Active PsA)	meyrutcsxu = idhjopovex mgwlbrwfix (yncpzaealu, xjghgeiboo - vxjwfjttjj)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis